Literature DB >> 3719521

Chondrosarcoma with additional mesenchymal component (dedifferentiated chondrosarcoma). I. A clinicopathologic study of 26 cases.

S Johnson, B Têtu, A G Ayala, S P Chawla.   

Abstract

During a 37-year period, 26 patients were seen who had chondrosarcoma with additional mesenchymal components ("dedifferentiated low-grade chondrosarcoma"). Sixteen were men and 10 were women aged 30 to 85 years (median, 61 years). The tumors' chondroid areas were of borderline or low-grade malignancy. The additional mesenchymal component was histologically classified as malignant fibrous histiocytoma (16), rhabdomyosarcoma (4), low-grade fibrosarcoma (3), osteosarcoma (2), and undifferentiated sarcoma (1). Preferred locations were pelvis (10) and femur (8). Symptoms had been present for 1 year or less in most cases. Pain was the most common symptom. In 15 of 26, major amputation was the primary treatment. Twelve patients received chemotherapy, usually after developing metastatic disease, but only one achieved a partial response. Median disease-free interval after diagnosis was 4 months, median survival was 6 months, and 19 patients died within 1 year. Of 4 who survived longer than 18 months, 3 presented with a low-grade fibrosarcoma. Survival and development of metastasis appeared unrelated to cell type, initial treatment, or chemotherapy, except when the tumor's initial nonchondroid component was low-grade fibrosarcoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3719521     DOI: 10.1002/1097-0142(19860715)58:2<278::aid-cncr2820580213>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

1.  Dedifferentiated chondrosarcoma of the larynx.

Authors:  O Sakai; H D Curtin; W C Faquin; R L Fabian
Journal:  AJNR Am J Neuroradiol       Date:  2000-03       Impact factor: 3.825

Review 2.  Therapeutic molecular targets in human chondrosarcoma.

Authors:  Nuor Jamil; Sarah Howie; Donald M Salter
Journal:  Int J Exp Pathol       Date:  2010-10       Impact factor: 1.925

3.  Pathobiology of selected tumors of the base of the skull.

Authors:  L Barnes
Journal:  Skull Base Surg       Date:  1991

4.  Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1.

Authors:  Rieko Oyama; Fusako Kito; Mami Takahashi; Marimu Sakumoto; Kumiko Shiozawa; Zhiwei Qiao; Rei Noguchi; Takashi Kubo; Shunichi Toki; Fumihiko Nakatani; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  Hum Cell       Date:  2019-02-08       Impact factor: 4.174

5.  Dedifferentiated chondrosarcoma of humerus with giant cell tumor-like features.

Authors:  T Ishida; H D Dorfman; E T Habermann
Journal:  Skeletal Radiol       Date:  1995-01       Impact factor: 2.199

Review 6.  Primary malignant mesenchymoma of bone: case report, literature review, and distinction of this entity from mesenchymal and dedifferentiated chondrosarcoma.

Authors:  S Kessler; J M Mirra; T Ishii; J C Thompson; E W Brien
Journal:  Skeletal Radiol       Date:  1995-05       Impact factor: 2.199

7.  siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells.

Authors:  Dae Won Kim; Kyung-Ok Kim; Mike J Shin; Jung Hee Ha; Sung Wook Seo; Jay Yang; Francis Y Lee
Journal:  Mol Cancer       Date:  2009-05-15       Impact factor: 27.401

8.  New clinically relevant, orthotopic mouse models of human chondrosarcoma with spontaneous metastasis.

Authors:  Jonathan Cm Clark; Toru Akiyama; Crispin R Dass; Peter Fm Choong
Journal:  Cancer Cell Int       Date:  2010-06-28       Impact factor: 5.722

9.  Maffucci's syndrome combined with dedifferentiated chondrosarcoma.

Authors:  H Tsuchiya; K Tomita; H Yasutake; Y Takagi; Y Ueda; M Kadoya
Journal:  Arch Orthop Trauma Surg       Date:  1991       Impact factor: 3.067

10.  Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma?

Authors:  Satoshi Kawaguchi; Tao Sun; Patrick P Lin; Michael Deavers; Nusrat Harun; Valerae O Lewis
Journal:  Clin Orthop Relat Res       Date:  2013-11-07       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.